Volunteers infected with a chloroquine-susceptible line of Plasmodium falciparum were adnministered standard oral chloroquine therapy at the first detection of parasites in the blood. Parasitemias progressed in the face of therapy for up to 5 days and to levels up to 100-fold greater than those at the initiation of treatment. Thereafter, infections cleared without a requirement for additional chemotherapy. This course of infection and response to treatment has not been previously reported and may have been detected because volunteers were exposed to an unusually large number of sporozoites. The observations are consistent with the hypothesis that prolonged parasitemia resulted from the continued release of merozoites from liver.
Oral administration of chloroquine to individuals with chloroquine-susceptible Plasmodium falciparum infection has been shown to result in the rapid arrest (within hours) and clearance (within days) of asexual erythrocytic parasites (16) . In contrast to this expected pattern of response, levels of parasitemia in some volunteer participants in a recent study of induced P. falciparum infection showed an increase for up to 5 days after the initiation of chloroquine treatment. For some individuals, the parasitemia 2 to 4 days after the start of treatment was 10 to 100 times greater than was the parasitemia at the initiation of treatment. Parasites causing the persisting parasitemias were chloroquine susceptible both in vivo and in vitro; thus, the continued development of infection could not be attributed to resistance to the drug. In this report, we present the course of these infections and offer explanations for continued chloroquine-susceptible P. falciparum parasitemia in the face of chloroquine treatment.
Data were obtained from 16 adult (median age, 24 years; range, 21 to 33 years) male participants in three separate studies in which P. falciparum NF-54 infections were induced through bites of about five infected mosquitoes per volunteer. Informed consent was obtained from all of the participants in these studies. The chloroquine; all volunteers had at least one rise in parasitemia after the initiation of chloroquine therapy. At times, posttherapy parasitemia was 100 times as high as it was at the initiation of therapy. Among individuals, the interval from the first to last detection of parasites ranged from 2 to 5 days; individual parasitemias varied from the lower limit of detection (about 6,000 to 10,000 parasites per ml) to about 1,500,000 parasites per ml. Particularly impressive were the marked changes in the level of parasitemia within short intervals. For example, the infection presented in panel 15 at days 9 and 10 was about 10,000 parasites per ml, yet at day 11, parasitemia was 1,500,000 parasites per ml.
Thick smears prepared after day 14 were negative for P. falciparum. The single course of chloroquine initiated at the indicated times was sufficient to cure infection in all volunteers.
Because of the preceding result, we reviewed the evolution of parasitemias in volunteers in two previous studies that used the same in vitro-cultured strain of P. falciparum. Panels 1 through 8 of Fig. 1 (4) is an estimate from dissections of paired salivary gland sporozoite densities, where 0 = no sporozoites seen; 1 = 1 to 10; 2 = 11 to 100; 3 = 101 to 1,000; and 4 = >1,000. Studies in human volunteers and animal models (7, 10, 12) have shown an inverse relationship between prepatent interval and the number of sporozoites inoculated.
consistent with the view that those mosquitoes used for study 3 transmitted an unnaturally large number of sporozoites to volunteers. We believe that the large number of sporozoites delivered in study 3 contributed to our capacity to track recurrent waves of parasitemia. If this view is correct, the pattems of parasitemia reported here would not be expected to be observed for malaria naturally acquired in the field. The proximal source of the parasites which comprised the late peaks in parasitemia is unknown. These could have been progeny of asexual erythrocytic stages which had reached a chloroquine-insusceptible form (i.e., schizonts [18] ) prior to the initiation of chloroquine therapy or which were sequestered in chloroquine-protected sites. This scenario is unlikely because the timing and magnitude of late peaks are difficult to reconcile with the known duration of the asexual erythrocytic cycle and the number of merozoites produced per schizont (1, 15) .
An alternative explanation is that continued parasitemia is attributable to continued merozoite release from the liver. It is known that liver infection is refractory to chloroquine therapy (2) . Further, because chloroquine does not inhibit merozoite invasion into erythrocytes (18) , parasites released from the liver would be expected to establish parasitemia in the face of chloroquine and thus, if released in sufficient number, be detected in thick smears. In the presence of chloroquine, parasites would not be expected to complete erythrocytic schizogony (13, 18) . The lack of fever (i.e., temperature >37.8°C; Fig. 1 ) in association with late peaks of parasitemia in study 3 is consistent with a failure of schizogony, since fever is associated with the rupture of schizonts (3) .
The observed pattern of parasitemia suggests the discontinuous release of merozoites from the liver with peaks of release occurring at about infection days 7, 9, and 11 to 12. Because it is established that human P. falciparum infection can comprise genetically different parasites (14) and because the P. falciparum used in these studies, NF-54, was not cloned, it is possible that recurrent waves of parasitemia reflect divergent exoerythrocytic maturation rates of genetically different lines.
It is informative to view the results from the perspective of the reporting scheme for chloroquine resistance of the World Health Organization (WHO) (17) . Specifically, in reference to the WHO Standard Test, which includes a 7-day postinitiation of therapy observation period, our demonstration of markedly increased parasitemia shortly after the initiation of therapy fits the pattern for RIII chloroquine resistance (the highest degree of resistance in the scheme). On the other hand, the demonstration that parasitemia was reduced by the single course of therapy to below detectable limits by 7 days after the initiation of treatment and that parasitemia did not reappear after day 7 fits the S classification (the greatest degree of susceptibility to chloroquine). Thus, the pattern of response observed seems an exception to the long-standing WHO scheme. We conclude that the explanation offered above is the most likely reason for the unexpected result. A possible alternative explanation would be that chloroquine treatment is more effective when applied against parasitemias of greater density (and of longer duration) than when initiated at very low parasitemia (WHO tests are normally performed when parasitemia is between 500,000 and 1,000,000 parasites per ml). We know of no evidence to support this possibility.
In future tests of vaccines against erythrocytic stages of P. falciparum, infections might be initiated either by intravenous injection of erythrocytes containing parasites or by injection of sporozoites by mosquito bite. The findings summarized in this report suggest that these methods might present very different challenges to host defenses. Injection of erythrocytic forms would represent a point source of parasites. In contrast, following sporozoite injection, parasites might be released into blood in waves over an interval of days and in numbers much larger than the number of parasites which would likely be contained in an injection of infected erythrocytes. The possibility that the first waves of parasites might modulate the capacity of host defenses to respond to subsequent releases of merozoites must be considered (11) .
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